News - Biotechnology
Australia’s IP trends reveal post-pandemic innovation shift
Australia’s life sciences sector continues to evolve amidst a dynamic landscape of intellectual property (IP) rights, particularly patents, which are […]
MoreNews - Biotechnology
CSL reshapes R&D while bracing for U.S. tariffs
Australia’s largest biotech company CSL is streamlining its R&D operations to enhance efficiency amidst a rapidly evolving global landscape. The […]
MoreNews - Biotechnology
National push to tackle cardiovascular and diabetes burden backs Aussie start-ups
Fourteen biotech and medtech innovators will share in a $12 million funding injection aimed at fast-tracking life-changing solutions for people […]
MoreNews - Biotechnology
Aussie-invented smart capsule wins regulatory nod
An ingestible gas-sensing capsule originally developed at RMIT University has received regulatory clearance from the U.S. Food and Drug Administration […]
MoreNews - Biotechnology
QBiotics reports promising data in rare cancer trial
On Rare Cancers Awareness Day (26 June), Australian biotech QBiotics Group unveiled the final efficacy and safety results from stage […]
MoreNews - Biotechnology
AusBiotech champions Australia’s momentum in the global life sciences race
AusBiotech has wrapped up a week packed with bilateral and multilateral engagements at the BIO International Convention 2025 in Boston. […]
MoreNews - Biotechnology
Local biotech earns green light to manufacture next-gen cell therapies
A Melbourne-based biotech company has secured a stem cell manufacturing licence from the Therapeutic Goods Administration (TGA), a move that […]
MoreNews - Biotechnology
NRF backs local ophthalmic biotech
A Melbourne-based biotechnology company has landed a game-changing investment to push forward its novel glaucoma implant to address the long-standing […]
MoreNews - Biotechnology
Purpose, policy and the future of clinical trials: Noxopharm CEO on what’s next for Australian biotech
As the world marks Clinical Trials Day (20 May), Dr Gisela Mautner, CEO of ASX-listed biotech Noxopharm, brings a bold […]
MoreNews - Biotechnology
World-first trial 3D prints skin directly onto wounds using robotic technology
In a world-first clinical trial, a robot developed by an Australian biotech company is being used to 3D print human […]
MoreRecent Posts in Pharma, MedTech & Biotech
Philips remote monitoring cuts hospital costs and ICU time by 69%
August 1, 2025
in News - MedTech & Diagnostics
VB Spine breaks ground in ANZ, Takes over Stryker’s spinal implants business
August 1, 2025
in News - MedTech & Diagnostics
New therapy PBS listed in advanced Parkinson’s disease
August 1, 2025
in News - Pharmaceuticals
PBS adds first ustekinumab and omalizumab biosimilars in inflammatory and allergic conditions
August 1, 2025
in News - Pharmaceuticals
November PBAC agenda unveiled amid tensions over tariff risks
July 31, 2025
in News - Pharmaceuticals
Promises, pitfalls and pressure points: Stakeholders weigh in on government’s AI healthcare report
July 31, 2025
in News - MedTech & Diagnostics
MSAC to consider funding for first TGA-approved TTVR device
July 31, 2025
in News - MedTech & Diagnostics
The triple squeeze on leaders and a messy middle: New future of work report
July 30, 2025
in Leadership & Management
Follow Us
Partner with us
News - MedTech & Diagnostics
Philips remote monitoring cuts hospital costs and ICU time by 69%
An innovative remote patient monitoring model has significantly improved post-operative care for patients, cutting ICU hours by 69% and saving […]
MoreNews - MedTech & Diagnostics
VB Spine breaks ground in ANZ, Takes over Stryker’s spinal implants business
VB Spine has officially taken the reins of Stryker’s spinal implants business in Australia and New Zealand. The transition builds […]
MoreNews - Pharmaceuticals
New therapy PBS listed in advanced Parkinson’s disease
A new therapeutic option for advanced Parkinson’s disease, Vyalev (foslevodopa with foscarbidopa), is now listed on the Pharmaceutical Benefits Scheme […]
MoreNews - Pharmaceuticals
PBS adds first ustekinumab and omalizumab biosimilars in inflammatory and allergic conditions
From 1 August 2025, two new biosimilars – SteQeyma (ustekinumab) and Omlyclo (omalizumab) – have been listed on the Pharmaceutical […]
More